Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans

Anti-Cancer Drugs

Volumn 10, Issue 8, 1999, Pages 705-710

  Loos, Walter J ^a   Verweij, Jaap ^a   Gelderblom, Hans J ^a   De Jonge, Maja J A ^a   Brouwer, Eric ^a   Dallaire, Brian K ^a,b   Sparreboom, Alex ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b BIOGEN   (United States)

Author keywords

9 Amino 20(S) camptothecin; Clinical pharmacokinetics; Erythrocytes; In vitro; Proteins; Rebound concentrations

Indexed keywords

9 AMINOCAMPTOTHECIN; ANTINEOPLASTIC AGENT; PLASMA PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MEMBRANE; CLINICAL ARTICLE; CLINICAL TRIAL; DIFFUSION; DRUG BIOAVAILABILITY; DRUG HYDROLYSIS; DRUG PROTEIN BINDING; ERYTHROCYTE; HUMAN; HUMAN CELL; PH; PRIORITY JOURNAL; REBOUND;

EID: 0033377034     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199909000-00003     Document Type: Article

References (28)

1. 1. Gerrits CJH, Jonge MJA de, Schellens JHM, Stoter G, Verweij J. Topoisomerase-I inhibitor: the relevance of prolonged exposure for present clinical development. Br J Cancer 1997; 76: 952-62.
2. 2. Hsiang Y, Hertzberg R., Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian topoisomerase I. J Biol Chem 1989; 260: 14873-8.
3. 3. Giovanella BC, Stehlin JS, Wall ME, et al. DNA Topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246: 1046-8.
4. 4. Dahut W, Harold N, Takimoto C, et al. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 1996; 14: 1236-44.
5. 5. Eder JP, Supko JG, Lynch T, et al. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Clin Cancer Res 1998; 4: 317-24.
6. 6. Pazdur R, Diaz-Canton E, Ballard WP, et al. Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. J Clin Oncol 1997; 15: 2905-9.
7. 7. Rubin E, Wood V, Bharti A, et al. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1995; 1: 269-76.
8. 8. Saltz LB, Kemeny NE, Tong W, Harrison J, Berkery R, Kelsen DP. 9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma. Cancer 1997; 80: 1727-32.
9. 9. Siu LL, Oza AM, Eisenhauer EA, et al. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks. J Clin Oncol 1998; 16: 1122-30.
10. 10. Jonge MJA de, Verweij J, Loos WJ, Dallaire BK, Sparreboom A. Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva. Clin Pharmacol Ther 1999; 65: 491-9.
11. 11. Jonge MJA de, Punt CJA, Gelderblom AJ, et al. Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors. J Clin Oncol 1999; 17: 2219-26.
12. 12. Mani S, Iyer L, Janisch L, et al. Phase I clinical and pharmacokinetic study or oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol 1998; 42: 84-7.
13. 13. Herben VMM, Gijn R van, Schellens JHM, et al. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors. J Clin Oncol 1999; 17: 1906-14.
14. 14. Hertzberg RP, Caranfa MJ, Holden KG, et al. Modification of the hydroxy-lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989; 32: 715-21.
15. 15. Takimoto CH, Dahut W, Marino MT, et al. Pharmacokinetics and pharmacodynamics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. J Clin Oncol 1997; 15: 1492-501.
16. 16. Herben VMM, Ten Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokin 1996; 31: 85-102.
17. 17. Rivory LP, Chatelut E, Canal P, Mathieu-Boué A, Robert J. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res 1994; 54: 6330-3.
18. 18. Burke TG, Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 1994; 37: 40-5.
19. 19. Sparreboom A, Jonge MJA de, Punt CJA, et al. Pharmacokinetics and bioavailability of oral 9-aminocamplothecin in adult patients with solid tumors. Clin Cancer Res 1998; 4: 1915-9.
20. 20. Loos WJ, Sparreboom A, Verweij J, Nooter K, Stoter G, Schellens JHM. Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection. J Chromatogr B 1997; 694: 435-41.
21. 21. Kerry R, Scrutton MC, Wallis RB. Mammalian platelet adrenoceptors. Br J Pharmacol 1984; 81: 91-6.
22. 22. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
23. 23. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13: 210-21.
24. 21. Catimel G, Chabot GG, Guastalla JP, et al. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 1995; 6: 133-40.
25. 25. Chabot GG, Abigerges D, Catimel G, et al. Population pharmacokinetics and pharmaco-dynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 1995; 6: 141-51.
26. 26. Highley MS, Bruijn EA de. Erythrocytes and the transport of drugs and endogenous compounds. Pharmacol Res 1996; 13: 186-95.
27. 27. Sparreboom A, Jonge MJA de, Bruijn P de, et al. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 1998; 4: 2747-54.
28. 28. Supko JG, Malspeis L. Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice. Cancer Res 1993; 53: 3062-9.